<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02739672</url>
  </required_header>
  <id_info>
    <org_study_id>ID-TAH-102</org_study_id>
    <nct_id>NCT02739672</nct_id>
  </id_info>
  <brief_title>Clinical Trial to Compare the Pharmacokinetics of TAH Tablet in Comparison to the Co-administration of Telmisartan, Amlodipine and Hydrochlorothiazide in Healthy Male Volunteers</brief_title>
  <official_title>A Randomized, Open-label, Single Dose, Replicate Crossover Clinical Trial to Compare the Pharmacokinetics of TAH Tablet in Comparison to the Co-administration of Telmisartan, Amlodipine and Hydrochlorothiazide in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IlDong Pharmaceutical Co Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IlDong Pharmaceutical Co Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      randomized, open-label, single dose, replicate crossover clinical trial to compare the
      pharmacokinetics of TAH tablet in comparison to the co-administration of telmisartan,
      amlodipine and hydrochlorothiazide in healthy male volunteers
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2, 2016</start_date>
  <completion_date type="Actual">April 6, 2016</completion_date>
  <primary_completion_date type="Actual">April 6, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUClast</measure>
    <time_frame>Hour 0 (Pre-dose), Hour 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 144(Total 18 points)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>Hour 0 (Pre-dose), Hour 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 144 (Total 18 points)</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>TAH tablet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Telmisartan/Amlodipine besylate/Hydrochlorothiazide tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Telmisartan+Amlodipine besylate+Hydrochlorothiazide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>coadministration of Telmisartan, Amlodipine besylate and Hydrochlorothiazide</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAH Tablet (Telmisartan/Amlodipine besylate/Hydrochlorothiazide)</intervention_name>
    <description>Telmisartan 80.0 mg, Amlodipine besylate 13.87 mg (Amlodipine 10 mg), Hydrochlorothiazide 25 mg combination-drug would be administered orally once</description>
    <arm_group_label>TAH tablet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TWYNSTA(Telmisartan+Amlodipine besylate)</intervention_name>
    <description>TWYNSTA 2 Tab. 40/5mg(Telmisartan 40 mg, Amlodipine besylate 6.935 mg(Amlodipine 5 mg) would be administered orally once</description>
    <arm_group_label>Telmisartan+Amlodipine besylate+Hydrochlorothiazide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydrochlorothiazide</intervention_name>
    <description>Dichlozid 1 Tab.(Hydrochlorothiazide 25.0 mg) would be administered orally once</description>
    <arm_group_label>Telmisartan+Amlodipine besylate+Hydrochlorothiazide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy male volunteers aged 19 to 55 years

          2. body mass index (BMI) of 17.5-30.5kg/m2 and weigh more than 55kg

          3. Subject does not have congenital or chronic disease and is without pathologic symptom
             or finding on medical exam.

          4. Subject was determined eligible according to the results of clinical laboratory tests
             like serum test, hematologic test, blood chemistry test, urine test etc. and vital
             signs, electrocardiography, physical exam etc. performed during the screening exam. 5)
             willing and able to provide written informed consent

        Exclusion Criteria:

          1. Evidence or history of clinically significant hematological, renal, endocrine,
             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or
             allergic disease (including drug allergies, but excluding untreated, asymptomatic,
             seasonal allergies at time of dosing)

          2. A subject with a history of gastrointestinal disease or surgery (except simple
             appendectomy or repair of hernia), which can influence the absorption of the study
             drug

          3. History of regular alcohol consumption (&gt; 210 g/week) within the 6 months before the
             screening visit.

          4. Subjects who take the medication involved in other clinical trials or bioequivalence
             tests within three months before the first dose medication characters.

          5. Seated systolic blood pressure &lt;100mmHg or ≥ 150 mmHg , or diastolic blood pressure of
             &lt;600mmHg or ≥ 100mmHg at the screening visit

          6. History of alcohol or drug abuse within the 12 months before the screening visit

          7. Subjects who treated with metabolizing enzyme inducers or inhibitors such as barbitals
             within 30days prior to the first dosing.

          8. Smoker who smoke more than 20 cigarettes per day

          9. Subjects who take ethical the count or over the count medicine within 10days before
             the first investigational product administration.

         10. Blood Subjects who do the whole blood donation within two months or component blood
             donation within 1month prior to the first dosing.

         11. Subjects who can increase risk due to clinical test and administration of drugs or has
             Severe grade / chronic medical, mental condition or abnormal laboratory result that
             may interfere with the analysis of test results.

         12. Subject with known for hypersensitivity reaction to TWYNSTA TAB or dihydropyridine
             derivatives

         13. Subject with known for hypersensitivity reaction to thiazide diuretics or Sulfonamides

         14. Patients with biliary obstructive disorder

         15. Patients receiving other drugs that affect RAAS such as Angiotensin Receptor
             Blocker(ARB), ACE inhibitors or aliskiren

         16. Combination with aliskiren in Diabetic patient or moderate to severe renal
             insufficient subjects (glomerular filtration rate&lt;60mL/min/1.73m2)

         17. Patients with severe hepatic impairment

         18. Patients with severe aortic stenosis

         19. Patients with history of shock

         20. Patients with anuria

         21. Patients with acute or severe renal failure

         22. Patients with hyponatraemia hypokalemia

         23. Patients with Addison's disease

         24. Patients with hypercalcemia of malignancy

         25. Who has Galactose intolerance, LAPP lactose intolerance, glucose-galactose
             malabsorption or genetic disorders

         26. Test subjects who is not willing or unable to comply with guidelines described in this
             protocol

         27. A person who is not determined unsuitable to participate in this test by the
             researchers
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Chonbuk National University Hospital</name>
      <address>
        <city>Chonbuk</city>
        <zip>561-712</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 31, 2016</study_first_submitted>
  <study_first_submitted_qc>April 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 15, 2016</study_first_posted>
  <last_update_submitted>January 24, 2017</last_update_submitted>
  <last_update_submitted_qc>January 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Telmisartan</mesh_term>
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Hydrochlorothiazide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

